NOTCH3 and non-small cell lung carcinoma: These findings may have important clinical implications, since the treatment of EGFR-driven NSCLC with EGFR inhibitors may cause the upregulation and enhanced activation of Notch1 and Notch3 [18,21], thus promoting the reversible shift of driver dependence from EGFR to Notch.